TCGA-39-5024-01A-21R-1820-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 65
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.480
- APICAL_SURFACE+0.430
- OXIDATIVE_PHOSPHORYLATION+0.360
- ESTROGEN_RESPONSE_LATE+0.320
- KRAS_SIGNALING_DN+0.300
- INTERFERON_GAMMA_RESPONSE+0.290
- ESTROGEN_RESPONSE_EARLY+0.270
- E2F_TARGETS+0.260
- PI3K_AKT_MTOR_SIGNALING+0.250
- MTORC1_SIGNALING+0.230
Top 10 suppressed
- PROTEIN_SECRETION-0.330
- TGF_BETA_SIGNALING-0.320
- UNFOLDED_PROTEIN_RESPONSE-0.220
- DNA_REPAIR-0.160
- ANGIOGENESIS-0.140
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.130
- MITOTIC_SPINDLE-0.110
- UV_RESPONSE_DN-0.110
- MYC_TARGETS_V2-0.070
- HEME_METABOLISM-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A07Z-01A-11R-A00Z-07 | — | B | 0.699 |
| 2 | C3N-03051 | — | cohortSQ1 | 0.687 |
| 3 | MDT-AP-0327 | Med | Medulloblastoma | 0.681 |
| 4 | C3N-03425 | — | cohortSQ1 | 0.671 |
| 5 | MDT-AP-0712 | Med | Medulloblastoma | 0.658 |
| 6 | SRR33532822 | — | C | 0.652 |
| 7 | GSM5359439 | — | — | 0.651 |
| 8 | sclcF7272_S56.txt | — | cohortA1 | 0.648 |
| 9 | SRR5088866 | — | — | 0.644 |
| 10 | MNG161 | — | — | 0.637 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.480 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.430 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.320 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.270 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.260 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.220 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.220 | Remibrutinib | — uncovered |
| COAGULATION | 0.220 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.210 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.190 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.160 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.140 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.130 | Inavolisib | — uncovered |